News Release

Estimated effectiveness of CoronaVac, Pfizer-BioNTech vaccines over time among patients with SARS-CoV-2 Omicron

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: In this case-control study with 164,000 participants, the CoronaVac and Pfizer-BioNTech vaccines were generally estimated to be effective against severe outcomes due to SARS-CoV-2 Omicron infection, but protection among older individuals was more likely to wane six months after the second dose. Hence, a booster dose is recommended for older patients to restore immunity. 

Authors: Ka Chun Chong, Ph.D., and Eng Kiong Yeoh, M.B.B.S., of the Chinese University of Hong Kong, are the corresponding authors. 

To access the embargoed study: Visit our For The Media website at this link


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.